CDNA CareDx, Inc.
XNAS
69.10
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CDNA
$69.10
—
Key stats
$69.10
- 52-Week Range
- $14.22 – $72.71
- YTD
- +261.02%
- IV Rank (30D)
- 79.72
- Straddle Price
- $12.50
- P/C Vol Ratio
- 0.11
- Market Cap
- $3.6B
- Open
- $68.87
- Day Range
- $68.33 – $70.31
- Volume
- 602,954
- Prev Close
- $69.21
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.32 |
| Cost of Equity (CAPM) | 12.39% (VRP-adj) |
| WACC | 12.40% |
| Volatility Risk Premium | +134.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 3.6% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 15 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 26.1% |
| Book / Price | 11.5% |
| Gross Margin (TTM) | 70.6% |
| FCF Margin (TTM) | 18.5% |
| Debt / Equity | 0.00 |
| Quality Score | 6/6 — compounder (15y DCF) |
| Market-Implied Growth | +23.0% (reverse-DCF on current price) |
| SMA 50 | $57.14 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $65.94 |
| Bollinger Width / SMA20 | 23.0% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $4B |
Peers used for multiples: CRSP, GH, LLY, MRNA, NTRA, TWST, VCYT, VRTX
60-Day Conviction
99%
20-Day Fair Value
≈ by Nov 24, 2026
$71.72
α +3.8%
rank 87%
conviction
99%
40-Day Fair Value
≈ by Dec 23, 2026
$73.19
α +5.9%
rank 82%
conviction
99%
60-Day Fair Value
≈ by Jan 21, 2027
$74.60
α +8.0%
rank 91%
conviction
99%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $106.85 | 21% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $73.62 | 9% | median 32.3× · 3 peers |
| Peer EV/EBITDA | $12.63 | 9% | median 26.9× · 3 peers |
| Peer P/B | $95.41 | 2% | median 12.0× · 7 peers |
| Peer P/S | $185.35 | 6% | median 19.6× · 8 peers |
| Market Anchor (SMA50) | $57.14 | 36% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $68.41 | 16% | 15 strikes · skew +0.14 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- SERVICES-MEDICAL LABORATORIES (8071) · industry map
- Exchange
- XNAS
- Market Cap
- $3.6B
- Employees
- 765
- List Date
- 2014-07-17
- CIK
- 0001217234
- Next Earnings
- 2026-10-29 (After-Close)
- EPS Forecast
- $0.07 (1 est.)
- Headquarters
- Brisbane, CA
- Homepage
- https://www.caredx.com
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA so…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 6.91% | -10.30% | 34.59% | -28.31% | 8.27% | 7.37% | 3.09% |
| Feb | -1.45% | -8.66% | 7.41% | 19.82% | -5.02% | -8.13% | 0.66% |
| Mar | -22.04% | -2.94% | -42.88% | -11.82% | -16.00% | -7.39% | -17.18% |
| Apr | 12.32% | -21.91% | -7.44% | -24.81% | -4.63% | 16.45% | -5.00% |
| May | 3.98% | -22.78% | -3.86% | 41.72% | 12.74% | 6.14% | 6.32% |
| Jun | 11.49% | -15.47% | 6.12% | 16.24% | 14.40% | 25.00% | 9.63% |
| Jul | -8.64% | 6.16% | 28.50% | 29.97% | -34.83% | 49.44% | 11.77% |
| Aug | -10.91% | -15.99% | -11.25% | 30.32% | 11.78% | 4.72% | 1.44% |
| Sep | -16.04% | -16.20% | -28.06% | 6.17% | 4.98% | 32.73% | -2.74% |
| Oct | -23.40% | 14.10% | -21.14% | -28.44% | 0.00% | 4.33%* | -9.09% |
| Nov | -14.96% | -35.41% | 79.48% | 8.39% | 20.99% | -- | 11.70% |
| Dec | 8.34% | -13.43% | 21.46% | -16.50% | 9.66% | -- | 1.91% |
| Total | -48.42% | -80.67% | 9.98% | 9.27% | 7.81% | 205.86% | 17.30% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $66.17
SMA 50: $57.62
SMA 200: $32.52
Current: $69.10
EMA 12: $67.28
EMA 26: $63.92
MACD: 3.3577 | Signal: -0.1065
BULLISH
ADX (14): 47.82
STRONG TREND
+DI: 20.67
−DI: 8.74
Momentum Oscillators
RSI (14): 63.74
NEUTRAL
Stoch %K: 69.16
Stoch %D: 72.45
Williams %R: -31.34
Volume & Volatility
BB Upper: $71.32
BB Lower: $61.02
NEUTRAL
OBV: 56,450,366
Vol SMA 20: 1,364,077
Vol ROC: -33.05%
ATR: $3.79
True Range: $1.98
HV 20: 50.9%
HV 30: 57.0%
HV 60: 52.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: CDNA
Executive Summary
BULLISH (Confidence Level: 8/10)
Key drivers:
- Technical momentum indicators (MACD, RSI) suggest an uptrend is in place.
- Recent positive news headlines have contributed to the stock's price appreciation.
Primary risks:
- High volatility (beta = 1.28), which may lead to significant price swings.
- Earnings miss or negative sentiment could negatively impact the stock.
Investment thesis: CDNA has been trending higher, driven by positive news and technical momentum indicators. However, high volatility and potential earnings misses remain key risks to consider.
Recent news sentiment impact: Positive news headlines have contributed to the stock's price appreciation, with a recent article highlighting CDNA's focus on core testing services having a POSITIVE sentiment.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish Medium-term (1-3 months): Bullish Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Lower band: $20.05 (strong support)
- Middle band: $21.11 (key resistance)
- Upper band: $22.18 (resistance)
Momentum Signals: RSI interpretation: 58.60 (neutral, not overbought or oversold) MACD signal: Bullish (0.40 / Signal: -0.06 / Histogram: 0.46) Bollinger Bands position: Neutral (price touching the middle band)
Volume Analysis: Volume SMA 20: 734099.90 On-Balance Volume (OBV): 33778850.44 (positive, indicating accumulation) Volume Rate of Change: -24.53% (indicating a decrease in volume)
News & Sentiment Analysis
Recent Headlines Summary:
- CareDx Sharpens Focus On Core Testing Services (Benzinga, 2026-04-16): POSITIVE sentiment
- No other recent news headlines have had a significant impact on the stock's price.
Sentiment Assessment: Overall sentiment is NEUTRAL, with one positive headline contributing to the bullish tone.
Catalyst Identification: Upcoming earnings report (date TBD) could provide additional catalysts or risks for the stock.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta = 1.28), indicating high volatility and potential price swings.
Volatility Regime: Current vs historical volatility levels: HIGH volatility is currently higher than its historical average.
Options Market Signals: IV rank is Low (11.7%), indicating historically low volatility, which could indicate a buy opportunity.
Downside Protection: Support levels:
- Lower band: $20.05 (strong support)
- Middle band: $21.11 (key resistance)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: NEUTRAL
Institutional Activity: Volume patterns suggesting institutional interest: Accumulation
Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.21 (low correlation), indicating a high degree of independence.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- Lower band: $20.05 (strong support)
- Middle band: $21.11 (key resistance)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Upper band: $22.18 (resistance)
Time-Sensitive Catalysts: Earnings report date TBD, which could provide additional catalysts or risks for the stock.
Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss at $20.05 to limit potential losses.
- Consider scaling into positions based on volume and sentiment.
By analyzing CDNA's technical indicators, news headlines, and risk metrics, we can conclude that the stock has been trending higher due to positive momentum indicators and recent news headlines. However, high volatility and potential earnings misses remain key risks to consider. A bullish thesis is supported by the technical analysis, but investors should be cautious of potential price swings and manage their risk accordingly.
Generated
News
All CDNA news →
Earnings History
19 of 24 under expected move
Avg Expected Move
16.60%
Avg Actual Move
9.20%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 6.20% | 2.91% | 0.47x | Within |
| 2021-05-05 | After-Close | 4.99% | 0.68% | 0.14x | Within |
| 2021-07-29 | After-Close | 8.97% | 3.97% | 0.44x | Within |
| 2021-10-28 | After-Close | 11.52% | 27.50% | 2.39x | Exceeded |
| 2022-01-10 | After-Close | 12.31% | 3.63% | 0.29x | Within |
| 2022-02-24 | After-Close | 13.47% | 1.88% | 0.14x | Within |
| 2022-05-05 | After-Close | 11.72% | 18.57% | 1.58x | Exceeded |
| 2023-02-27 | After-Close | 13.26% | 14.34% | 1.08x | Exceeded |
| 2023-05-10 | After-Close | 20.37% | 2.68% | 0.13x | Within |
| 2023-08-08 | After-Close | 18.84% | 11.23% | 0.60x | Within |
| 2023-11-08 | After-Close | 30.49% | 13.90% | 0.46x | Within |
| 2024-01-09 | After-Close | 9.86% | 0.65% | 0.07x | Within |
| 2024-02-28 | After-Close | 21.40% | 9.47% | 0.44x | Within |
| 2024-05-09 | After-Close | 19.44% | 34.09% | 1.75x | Exceeded |
| 2024-07-31 | After-Close | 18.63% | 17.96% | 0.96x | Within |
| 2024-10-15 | After-Close | 10.72% | 0.65% | 0.06x | Within |
| 2024-11-04 | After-Close | 19.95% | 0.13% | 0.01x | Within |
| 2025-02-26 | After-Close | 21.45% | 0.19% | 0.01x | Within |
| 2025-04-30 | After-Close | 19.40% | 10.72% | 0.55x | Within |
| 2025-08-06 | After-Close | 22.33% | 7.86% | 0.35x | Within |
| 2025-11-04 | After-Close | 30.48% | 13.84% | 0.45x | Within |
| 2026-02-24 | After-Close | 18.57% | 4.10% | 0.22x | Within |
| 2026-04-28 | After-Close | 20.54% | 5.07% | 0.25x | Within |
| 2026-07-30 | After-Close | 13.58% | 14.72% | 1.08x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
CDNA Options Activity & IV Rank
CDNA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 81.6%
7-DTE IV: —
Expected Move: $12.50
7-DTE Move: $12.50
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 769
Put Volume: 85
P/C Volume: 0.111
BULLISH
Call OI: 2,476
Put OI: 7,132
P/C OI: 2.88
Total OI: 9,608
ATM Options Pricing
ATM Call: $5.55
ATM Put: $6.95
Call %: 8.0%
Put %: 10.1%
Chain Summary
Chain Volume: 1,473
Chain OI: 12,494
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 93rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
93%
vs own history
GEX tilt
+0.62
OI-weighted, today
Vanna tilt
+0.84
δ-sensitivity to IV
Charm tilt
-0.87
δ-decay vs time
Vanna tilt +0.84: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.87: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 10 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 85.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)79.7HighOct 26
Straddle Price (30 DTE)$12.50Oct 26
Beta Analysis
Risk Metrics
Beta: 1.3901
Alpha: 160.22%
Correlation: 0.2426
R-Squared: 5.9%
Stock Volatility: 73.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
CDNA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 53,394,196 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$1.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $897.75K | 57.07% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $401.85K | 25.54% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $273.60K | 17.39% | 2026-06-30 |
2 filers$34.20K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $31.35K | 91.67% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $2.85K | 8.33% | 2026-06-30 |
CDNA Insider Trading (Form 4)
Latest: 2026-10-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Jessica Meng | Chief Commercial Officer | Tax (F) | −2,619 | $66.23 | -$173.5K | EDGAR |
| 2026-10-05 | Keith Kennedy | CFO & COO | Tax (F) | −3,018 | $66.23 | -$199.9K | EDGAR |
| 2026-10-05 | Jeffrey Adam Novack | Secretary and General Counsel | Tax (F) | −997 | $66.23 | -$66.0K | EDGAR |
| 2026-10-05 | John Walter Hanna JR | President and CEO | Tax (F) | −8,511 | $66.23 | -$563.7K | EDGAR |
| 2026-10-05 | Michael Goldberg | Director | Award (A) | +588 | — | EDGAR | |
| 2026-09-15 | Jessica Meng | Chief Commercial Officer | Tax (F) | −6,688 | $52.37 | -$350.3K | EDGAR |
| 2026-09-15 | Keith Kennedy | CFO & COO | Tax (F) | −8,220 | $52.37 | -$430.5K | EDGAR |
| 2026-08-06 | George Bickerstaff | Director | Sell (S) | −20,000 | $46.28 | -$925.7K | EDGAR |
| 2026-08-06 | Michael Goldberg | Director | Sell (S) | −44,700 | $47.06 | -$2.10M | EDGAR |
| 2026-08-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell (S) | −2,688 | $46.26 | -$124.3K | EDGAR |
| 2026-08-06 | Christine Cournoyer | Director | Sell (S) | −16,000 | $46.94 | -$751.0K | EDGAR |
| 2026-08-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell (S) | −2,688 | $46.26 | -$124.3K | EDGAR |
| 2026-08-06 | George Bickerstaff | Director | Sell (S) | −20,000 | $46.28 | -$925.7K | EDGAR |
| 2026-08-06 | Michael Goldberg | Director | Sell (S) | −44,700 | $47.06 | -$2.10M | EDGAR |
| 2026-08-06 | Christine Cournoyer | Director | Sell (S) | −16,000 | $46.94 | -$751.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CDNA Insider Holdings
16 insiders · @ $69.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John Walter Hanna JR | President and CEO | 644,937 | $44.57M | -$6.37M | 14 | 2026-10-05 |
| 2 | Abhishek Jain | Chief Financial Officer | 319,725 | $22.09M | -$4.7K | 26 | 2025-08-05 |
| 3 | Peter Maag | Director | 309,846 | $21.41M | -$48.01M | 110 | 2025-07-10 |
| 4 | Keith Kennedy | CFO & COO | 208,686 | $14.42M | $0 | 9 | 2026-10-05 |
| 5 | Fred E Cohen | Director | 165,060 | $11.41M | $0 | 34 | 2026-06-16 |
| 6 | Jessica Meng | Chief Commercial Officer | 158,980 | $10.99M | $0 | 8 | 2026-10-05 |
| 7 | Michael Goldberg | Director | 153,371 | $10.60M | -$12.72M | 81 | 2026-10-05 |
| 8 | George Bickerstaff | Director | 134,061 | $9.26M | -$5.57M | 67 | 2026-08-06 |
| 9 | Jeffrey Adam Novack | Secretary and General Counsel | 105,078 | $7.26M | -$948.9K | 32 | 2026-10-05 |
| 10 | Nathan Smith | Chief Financial Officer | 75,000 | $5.18M | $0 | 2 | 2026-02-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CDNA Board & Officers
As of SEC filings through Oct 5, 2026Directors 10
- Fred E Cohen · since Jul 16, 2014
- George Bickerstaff · since Jul 16, 2014
- Michael Goldberg · since Jul 16, 2014
- William A Hagstrom · since Mar 4, 2015
- Christine Cournoyer · since Sep 1, 2019
- Hannah Valantine · since Jul 1, 2021
- Arthur A Torres · since Sep 15, 2021
- Richard Bryan Riggsbee · since Mar 11, 2024
- John Walter Hanna JR · since Apr 15, 2024
- Suresh Gunasekaran · since Oct 22, 2025
Officers 4
- John Walter Hanna JR · President and CEO · since Apr 15, 2024
- Keith Kennedy · CFO & COO · listed since Apr 2026
- Jessica Meng · Chief Commercial Officer · since Sep 12, 2024
- Jeffrey Adam Novack · Secretary and General Counsel · since Apr 24, 2024
Changes in the last 10 years (42)
| Apr 3, 2026 | Keith Kennedy listed as CFO & COO (previously Chief Operating Officer) in SEC filings |
| Feb 24, 2026 | The company announced the departure of Nathan Smith as Chief Financial Officer in an SEC filing |
| Oct 22, 2025 | Suresh Gunasekaran became a director |
| Aug 7, 2025 | Nathan Smith became Chief Financial Officer |
| Aug 6, 2025 | The company announced the departure of Abhishek Jain as Chief Financial Officer in an SEC filing |
| Sep 12, 2024 | Keith Kennedy became Chief Operating Officer |
| Sep 12, 2024 | Jessica Meng became Chief Commercial Officer |
| Sep 6, 2024 | The company announced the departure of Alexander L Johnson as President of Patient and Testing Services in an SEC filing |
| Apr 24, 2024 | Jeffrey Adam Novack became Secretary and General Counsel |
| Apr 15, 2024 | John Walter Hanna JR became a director |
| Apr 15, 2024 | John Walter Hanna JR became President and CEO |
| Mar 11, 2024 | Richard Bryan Riggsbee became a director |
| Jan 4, 2024 | Alexander L Johnson listed as President of Patient and Testing Services (previously Chief Business Officer) in SEC filings |
| Oct 30, 2023 | The company announced the departure of Reginald Seeto from the board in an SEC filing |
| Oct 30, 2023 | The company announced the departure of Reginald Seeto as President and Chief Executive Officer in an SEC filing |
| Sep 20, 2023 | The company announced the departure of Abraham Ronai as Chief Administrative & Legal Officer and Secretary in an SEC filing |
| Nov 21, 2022 | The company announced the departure of Ralph Snyderman from the board in an SEC filing |
| Sep 9, 2022 | Abraham Ronai first on file as Chief Administrative & Legal Officer and Secretary |
| Sep 9, 2022 | Abhishek Jain listed as Chief Financial Officer (previously Interim Chief Financial Officer) in SEC filings |
| Aug 30, 2022 | The company announced the departure of Sasha King as Chief Marketing Officer in an SEC filing |
| May 26, 2022 | Abhishek Jain became Interim Chief Financial Officer |
| May 18, 2022 | The company announced the departure of Ankur Dhingra as Chief Financial Officer in an SEC filing |
| Nov 1, 2021 | The company announced the departure of Peter Maag from the board in an SEC filing |
| Nov 1, 2021 | The company announced the departure of Peter Maag as Executive Chair in an SEC filing |
| Sep 15, 2021 | Arthur A Torres became a director |
| Jul 19, 2021 | Alexander L Johnson became Chief Business Officer |
| Jul 1, 2021 | Hannah Valantine became a director |
| Mar 25, 2021 | Ankur Dhingra became Chief Financial Officer |
| Jan 27, 2021 | Sasha King listed as Chief Marketing Officer (previously Chief Commercial Officer) in SEC filings |
| Dec 31, 2020 | Marcel Konrad became an officer |
| Nov 5, 2020 | Peter Maag listed as Executive Chair (previously Chief Executive Officer) in SEC filings |
| Nov 2, 2020 | Reginald Seeto listed as President and Chief Executive Officer (previously President and Chief Business Officer) in SEC filings |
| Nov 2, 2020 | Reginald Seeto first listed as a director in an SEC filing |
| Sep 1, 2019 | Christine Cournoyer became a director |
| Jul 1, 2019 | Grace Colon became a director |
| May 13, 2019 | Peter Maag listed as Chief Executive Officer (previously President and Chief Executive Officer) in SEC filings |
| Nov 26, 2018 | Reginald Seeto became President and Chief Business Officer |
| Nov 2, 2018 | Neil Gagnon reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2018 | Amy Abernethy became a director |
| Oct 20, 2017 | Sasha King became Chief Commercial Officer |
| Jul 3, 2017 | Invest AB Midroc became a 10% owner |
| Apr 21, 2017 | Michael Brian Bell became Chief Financial Officer |
Not reported recently (12)
- Grace Colon · Last reported as a director in an SEC filing dated Jun 21, 2023
- Marcel Konrad · Last reported as an officer in an SEC filing dated Jan 5, 2021
- Michael Brian Bell · Last reported as Chief Financial Officer in an SEC filing dated Nov 3, 2020
- James P Yee · Last reported as Chief Medical Officer in an SEC filing dated Jul 1, 2019
- Amy Abernethy · Last reported as a director in an SEC filing dated Jan 23, 2019
- Mitchell J Nelles · Last reported as Chief Operating Officer in an SEC filing dated Jul 12, 2018
- John Joseph Sninsky · Last reported as Chief Scientific Officer in an SEC filing dated Jan 30, 2018
- Anders Karlsson · Last reported as Chief International Business Officer in an SEC filing dated Jan 25, 2018
- Invest AB Midroc · Last reported as a 10% owner in an SEC filing dated Jul 7, 2017
- Douglas S Miller · Last reported as a director in an SEC filing dated Apr 4, 2017
- Charles Constanti · Last reported as Chief Financial Officer in an SEC filing dated Feb 22, 2017
- Todd Whitson · Last reported as Chief Commercial Officer in an SEC filing dated Feb 22, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CDNA Proposed Insider Sales (Form 144)
Latest: 2026-08-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
15 filings
· $14.7M notice value
· 6 unique filers
· 7% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
PETER MAAG (9, $9.1M) · CHRISTINE COURNOYER (2, $2.3M) · MICHAEL D. GOLDBERG FAM TRUST (1, $2.1M) · GEORGE W BICKERSTAFF (1, $926K) · ARTHUR TORRES (1, $200K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | PETER MAAG | Director | 9,122 | $423.1K | 2026-08-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-14 | PETER MAAG | Director | 7,000 | $317.1K | 2026-08-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-13 | PETER MAAG | Director | 7,000 | $329.5K | 2026-08-13 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-12 | PETER MAAG | Director | 7,000 | $328.2K | 2026-08-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-11 | PETER MAAG | Director | 7,000 | $333.9K | 2026-08-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-10 | PETER MAAG | Director | 6,902 | $328.9K | 2026-08-10 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-10 | ARTHUR TORRES | Director | 4,200 | $200.5K | 2026-08-10 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-07 | PETER MAAG | Director | 27,332 | $1.25M | 2026-08-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-05 | PETER MAAG | Director | 46,963 | $2.18M | 2026-08-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-05 | JEFFREY NOVACK | Officer | 2,688 | $126.6K | 2026-08-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
84 ETFs hold CDNA
25 shown · $557.51M total exposure · 0.14% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $101.5M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.94% | $97.0M | $10.4B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.12% | $89.3M | $74.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $37.8M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.24% | $33.2M | $13.7B | 2026-10-23 |
| 6 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.08% | $27.6M | — | 2026-10-23 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.23% | $24.9M | $10.7B | 2026-10-23 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.11% | $19.4M | — | 2026-09-30 |
| 9 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.02% | $15.3M | — | 2026-10-23 |
| 10 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.21% | $14.1M | $6.6B | 2026-10-23 |
| 11 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.17% | $12.6M | — | 2026-10-23 |
| 12 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.88% | $10.8M | $1.2B | 2026-10-23 |
| 13 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.69% | $9.1M | $1.3B | 2026-10-23 |
| 14 | VHT Vanguard Health Care ETF | Vanguard | 0.04% | $8.7M | — | 2026-09-30 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.23% | $7.4M | $3.2B | 2026-10-23 |
| 16 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.55% | $5.7M | $1.0B | 2026-10-23 |
| 17 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $5.7M | — | 2026-05-31 |
| 18 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.55% | $5.5M | $1.0B | 2026-10-23 |
| 19 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $5.0M | $96.5B | 2026-10-23 |
| 20 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.20% | $5.0M | $2.5B | 2026-10-23 |
| 21 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.18% | $4.7M | $2.7B | 2026-10-23 |
| 22 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.33% | $4.5M | $1.4B | 2026-10-23 |
| 23 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.10% | $4.3M | $4.2B | 2026-10-23 |
| 24 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 1.18% | $4.2M | $360.8M | 2026-10-23 |
| 25 | BRES Burney U.S. Equity Select ETF | Nport | 0.60% | $4.0M | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
33.38
TTM Diluted EPS
$2.07
TTM Revenue
$458.09M
TTM Net Income
$111.01M
TTM Op. Cash Flow
$93.66M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $131.95M | $110.64M | $2.07 | $30.60M |
| Q1 '26 | 2026-03-31 | $117.70M | $2.81M | $0.05 | $4.33M |
| Q4 '25 | 2025-12-31 | $108.39M | $-4.11M | $-0.08 | $21.36M |
| Q3 '25 | 2025-09-30 | $100.06M | $1.68M | $0.03 | $37.36M |
| Q2 '25 | 2025-06-30 | $86.68M | $-8.57M | $-0.16 | $9.89M |
| Q1 '25 | 2025-03-31 | $84.69M | $-10.35M | $-0.19 | $-26.58M |
| Q4 '24 | 2024-12-31 | $86.58M | $87.70M | $1.60 | $21.89M |
| Q3 '24 | 2024-09-30 | $82.88M | $-10.64M | $-0.20 | $12.52M |
| Q2 '24 | 2024-06-30 | $92.27M | $-4.62M | $-0.09 | $18.95M |
| Q1 '24 | 2024-03-31 | $72.05M | $-19.89M | $-0.38 | $-15.31M |
| Q4 '23 | 2023-12-31 | $65.57M | $-118.10M | $-2.20 | $-8.38M |
| Q3 '23 | 2023-09-30 | $67.19M | $-23.48M | $-0.43 | $-10.18M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
33.38
P/B
8.67
P/S
8.05
EV/EBITDA
325.89
EV/Sales
7.24
ROE
26.1%
ROA
20.8%
Div Yield
0.00%
FCF Yield
2.54%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$3.69B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.59M
SI % of Float
13.12%
Days to Cover
4.56
Short Vol Ratio
46.0%
Free Float
50.19M
Float %
97.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14